Clinical trials
Leukemia clinical trials
Cancer of the blood and bone marrow that affects how blood cells are made. We’re tracking 1,319 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06247501RecruitingPhase 2
CAR-T therapy for children with B-cell ALL needing transplant
This study tests a new type of immune-cell therapy (called CAR-T cells) for children and young adults with a specific blood cancer (B-cell ALL) who need a stem cell transplant. The treatment uses a patient's own T-cells that are modified to find and kill cancer cells with the CD19 marker.
SeoulAges Up to 25 years - NCT06076226Recruiting
Donor telomere length and leukemia transplant outcomes
This trial looks at whether the length of telomeres (the protective caps at the ends of chromosomes) in donor blood cells affects recovery for people with acute leukemia who receive a stem cell transplant. It aims to see if a simple donor blood test can predict how well the transplant works.
Hangzhou, ZhejiangAges 5–90 - NCT06058572RecruitingPhase 2
Rifaximin for gut bacteria after stem cell transplant in leukemia
This trial tests whether the antibiotic rifaximin can help protect the healthy bacteria in your gut after a stem cell transplant for acute leukemia. It may reduce infections and other complications during your recovery.
Navi Mumbai, MaharashtraAges 18–70 - NCT05445154RecruitingPhase 1/Phase 2
New treatment for newly diagnosed FLT3 AML with oral drugs
This Phase 1/2 study tests SKLB1028 (with daunorubicin and cytarabine) in people with newly diagnosed acute myeloid leukemia (AML) who have an FLT3 mutation. It aims to see how well and how safely this treatment works for this specific type of AML.
ChengduAges 18–59 - NCT04478006Recruiting
Translational research for childhood blood cancers
This study looks at childhood leukemia and related blood disorders. It may help researchers learn more about the diseases and how to improve treatments for children.
Hong Kong, HksarAges Up to 18 years - NCT04157569Recruiting
Study blood DNA markers after chemotherapy in older acute leukemia
This trial checks a blood test called “ctDNA” (tiny pieces of leukemia DNA in blood) after chemotherapy. It may help doctors understand how well treatment is working in older adults with acute leukemia.
BeijingAges 60–100 - NCT03013998RecruitingPhase 1/Phase 2
Biomarker-guided treatment study for older adults with AML
This trial studies whether choosing treatment based on lab test “biomarkers” (specific genetic or blood markers) can help people with acute myeloid leukemia (AML). It focuses on adults who are not good candidates for the most intensive chemotherapy, and it uses different sub-studies for different AML types.
Phoenix, ArizonaAges 18 years+ - NCT04224974Recruiting
Engagement and symptom support for newly diagnosed acute leukemia
This trial tests an emotion- and symptom-focused way of engaging with care for people who are newly diagnosed with acute leukemia and starting intensive “induction” treatment aimed at cure. It may help you feel better supported and better able to manage distressing symptoms during a critical early phase of treatment.
Hamilton, OntarioAges 18 years+ - NCT02869516Recruiting
Acute leukemia patient database study
This study enrolls people who have been diagnosed with acute leukemia and collects health information in a database. It may help doctors better understand care outcomes and improve future treatment planning.
Marseille, Bouches-du RhôneAges 18 years+ - NCT06224257RecruitingPhase 2
Linperlisib for relapsed or refractory T-LGLL
This trial tests a new drug called Linperlisib for people with a rare type of leukemia (T-cell large granular lymphocytic leukemia) that has come back or stopped responding to previous treatment. It's a possible option for patients whose blood counts are low, who have an enlarged spleen, or who have other related health problems.
Hefei, AnhuiAges 18 years+ - NCT07074496RecruitingEarly Phase 1
Combined cell therapy for newly diagnosed Ph+ ALL
This trial tests a new combination treatment using ThisCART19A cells and olverembatinib in adults newly diagnosed with a type of leukemia that has the Philadelphia chromosome. It aims to see if this approach is safe and effective.
Suzhou, JiangsuAges 18 years+ - NCT07237230Recruiting
Gamma-delta T cells to prevent leukemia relapse after transplant
This trial tests if a special type of immune cell called gamma-delta T cells can help prevent acute myeloid leukemia from coming back after a stem cell transplant. It is for people with high-risk features who have recently had a transplant.
Wuhan, HubeiAges 18–65 - NCT07604064RecruitingPhase 2
IDH1 Inhibitor Treatment for Relapsed or Refractory Blood Cancer
This trial tests a drug called olutasidenib in Japanese patients with acute myeloid leukemia (a serious blood cancer) that has come back or stopped responding to previous treatment. The drug targets a specific genetic change (IDH1 mutation) that some leukemia cells have, and may help patients whose cancer is difficult to treat.
Tokyo and Other Japanese CitiesAges 18 years+ - NCT07040982RecruitingPhase 1
Asciminib after cell therapy for Ph+ ALL
This trial tests the drug asciminib after a stem cell transplant or CAR T-cell therapy for adults with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) to help prevent the cancer from coming back.
Duarte, CaliforniaAges 18 years+ - NCT06397027RecruitingPhase 1
Ziftomenib, venetoclax, and azacitidine for pediatric leukemia
This trial tests a new drug combination (ziftomenib, venetoclax, and azacitidine) in children and young adults with acute leukemia that has come back or not responded to treatment. It may help if your child's leukemia has certain genetic changes (like KMT2A, NPM1, or NUP98).
Houston, TexasAges 2–21 - NCT06082934RecruitingPhase 1/Phase 2
Triple drug combo for newly diagnosed Ph+ ALL
This trial tests a combination of three targeted drugs (olverembatinib, venetoclax, and dexamethasone) for people newly diagnosed with a specific type of leukemia called Ph+ ALL. The goal is to see if this combination can help control the disease without needing traditional chemotherapy.
Xi'an, ShannxiAges 18 years+ - NCT07470073RecruitingEarly Phase 1
Universal CAR-T cell therapy for B-cell leukemia (ages 12-75)
This trial tests a new type of CAR-T cell therapy (called universal CAR-T) that targets CD19 and CD20 markers on cancer cells. It is for people aged 12 to 75 with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back after treatment.
Wuhan, HubeiAges 12–75 - NCT06585345RecruitingPhase 1/Phase 2
CD7 CAR-T for relapsed or refractory acute leukemia
This trial tests a new immune therapy called CD7 CAR-T cells for people with acute leukemia that has come back or hasn't gotten better with standard treatments. It aims to see if this treatment is safe and can help control the leukemia.
Chengdu, SichuanAges 14–65 - NCT07375355Recruiting
A study of Scemblix for newly diagnosed chronic myeloid leukemia in China
This study looks at how well the medicine Scemblix (asciminib) works for people in China who have just been diagnosed with a certain type of leukemia (chronic myeloid leukemia in chronic phase). It aims to see if starting this treatment soon after diagnosis is effective and safe.
Wuhan, HubeiAges 18–99 - NCT06803745Recruiting
Comparing two radiation doses for leukemia transplant
This trial tests whether a lower or higher dose of total body irradiation works better for people with acute leukemia getting a stem cell transplant for the first time. It aims to find the safest and most effective radiation level to prepare your body for the transplant.
Baltimore, MarylandAges Any age - NCT06937554Recruiting
Function and nutrition in fit leukemia patients
This trial looks at how exercise and nutrition affect fit adult leukemia patients during intensive chemotherapy. It aims to understand how to best support your recovery and well-being.
Rome, RMAges 18–70 - NCT05749276RecruitingPhase 1
Daratumumab with chemo for older adults with high-risk AML
This Phase 1 study tests whether adding daratumumab to standard intensive chemotherapy (idarubicin and cytarabine) works safely in people age 60 or older with a higher-risk form of acute myeloid leukemia (AML). It may help improve outcomes, but the main goal is to find the best dosing and safety in this age group.
NantesAges 60 years+ - NCT07101497RecruitingPhase 2
BN104 as maintenance therapy after stem cell transplant for leukemia
This trial tests a new drug called BN104 to help keep leukemia from coming back after a stem cell transplant. It's for people with certain types of acute leukemia that have specific gene changes.
Suzhou, JiangsuAges 12 years+ - NCT06394011RecruitingPhase 2
New drug combo for intermediate/high risk AML
This trial tests a new combination of drugs (VA plus HAAG) for adults newly diagnosed with intermediate or high-risk AML. It aims to see if this combination is safe and effective for people who haven't had prior treatment.
Suzhou, JiangsuAges 18–65
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for leukemia?
- Yes. Clin2 currently lists 1,319 recruiting leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.